MedTrace Logo

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

NCT02589626 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-01-07

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

empagliflozin 10mg

DRUG

empagliflozin 25 mg

DRUG

Placebo

For blinding purposes

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-29
Primary Completion
2017-06-02
Completion
2017-06-02

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02589626 on ClinicalTrials.gov